List view / Grid view

Everolimus (Afinitor)

 

news

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.